Autolus announces closing of Initial Public Offering

26 June 2018

UCLB Spinout, Autolus announces closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares.

Autolus Therapeutics plc today announced the closing of its previously announced initial public offering in the United States of 10,147,059 American Depositary Shares (“ADSs”), representing 10,147,059 ordinary shares, at an initial public offering price of $17.00 per ADS, which includes an additional 1,323,529 ADSs issued upon the exercise in full by the underwriters of their option to purchase additional ADSs. Aggregate net proceeds to Autolus, after underwriting discounts but before estimated offering expenses, were $160.4 million. All of the ADSs were offered by Autolus.

The clinical stage biopharmaceutical company was founded upon the work of Dr Martin Pule, a UCL academic, clinical haematologist and thought leader in T-cell engineering.

Read the full press release here

 

2018-06-26T15:53:27+00:00